Brightsurf Science News & Current Events

September 08, 2019
Phase 1 study shows novel KRAS inhibitor well tolerated by patients with adenocarcinoma and non-small cell lung cancer
A clinical trial testing the toxicity of a KRAS inhibitor demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation, according to research presented today at the IASLC 2019 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.

Fatty foods necessary for vitamin E absorption, but not right away
A fresh look at how to best determine dietary guidelines for vitamin E has produced a surprising new finding: Though the vitamin is fat soluble, you don't have to consume fat along with it for the body to absorb it.

New KEYNOTE 021 data shows no association with tumor mutational burden
Researchers had previously reported data from the KEYNOTE 021 trial that showed antitumor activity for pembrolizumab plus platinum-based chemotherapy in untreated advanced nonsquamous non-small cell lung cancer patients.

Nivolumab combined with ipilimumab safe as first-line therapy for lung cancer patients
Combining the PD-1 immune check point inhibitor nivolumab with the monoclonal antibody ipilimumab showed a consistent safety profile in special populations with advanced non-small cell lung cancer (NSCLC), according to research presented today by at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.

Scientists find psychiatric drugs affect gut contents
Scientists have found that antidepressants and other psychiatric drugs can change the quantity and composition of gut bacteria in rats.

Keynote 189: Tumor mutational burden not significantly associated with efficacy of pembrolizumab
Tumor mutational burden was not significantly associated with efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy as first-line therapy for metastatic nonsquamous non-small cell lung cancer, according to research reported today by Dr.

Children of anxious mothers twice as likely to have hyperactivity in adolescence
A large study has shown that children of mothers who are anxious during pregnancy and in the first few years of the child's life have twice the risk of having hyperactivity symptoms at age 16.

BioMILD trial demonstrates lung cancer screening using microrna blood test enhance prevention effort
Lung cancer screening efforts have accelerated in the last decade, with researchers showing that low dose CT screening is effective in reducing lung cancer mortality.

Native foods are key to preserving rodent gut bacteria in captivity
If a woodrat is in captivity and is eating an artificial diet, that finely tuned gut microbiome changes.

New breakthrough: Photomultiplication type all-polymer photodetectors with single carrier transport
The optimal photomultiplication (PM) type all-PPDs with PBDB-T:PZ1 (100:3, wt/wt) as active layers exhibit EQE of > 100% from 310 to 790 nm.

The Lancet: Malaria can and should be eradicated within a generation, declare global health experts
Authored by 41 of the world's leading malariologists, biomedical scientists, economists, and health policy experts, this seminal report synthesizes existing evidence with new epidemiological and financial analyses to demonstrate that -- with the right tools, strategies, and sufficient funding - eradication of the disease is possible within a generation.

Mutations associated with sensitivity or resistance to immunotherapy in mNSCLC
The relationship between gene alterations and response to anti-PD-L1 with and without anti-CTLA-4 are not well characterized.

Analysis from the MYSTIC Trial
The relationship between gene alterations and response to An update from the Phase III MYSTIC study showed poorer outcomes across treatment arms in patients with metastatic non-small cell lung cancer and mutations in STK11 or KEAP1 genes compared with those without the corresponding mutations.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.